|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DJ-1's effect on Nrf2 and subsequent effects on antioxidant responses may explain how DJ-1 affects the etiology of both cancer and PD, which are seemingly disparate disorders.
|
17015834 |
2006 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Activation of the Nrf2-ARE signaling pathway: a promising strategy in cancer prevention.
|
16435293 |
2006 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
(2006) provide evidence in a recent issue of Molecular Cell to support the notion that elevated Nrf2 activity may also play a role in the evolution of cancer.
|
16543142 |
2006 |
|
Lung Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer.
|
16507366 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Loss of KEAP1 function leading to constitutive activation of NRF2-mediated gene expression in cancer suggests that tumor cells manipulate the NRF2 pathway for their survival against chemotherapeutic agents.
|
17020408 |
2006 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
DJ-1's effect on Nrf2 and subsequent effects on antioxidant responses may explain how DJ-1 affects the etiology of both cancer and PD, which are seemingly disparate disorders.
|
17015834 |
2006 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Loss of KEAP1 function leading to constitutive activation of NRF2-mediated gene expression in cancer suggests that tumor cells manipulate the NRF2 pathway for their survival against chemotherapeutic agents.
|
17020408 |
2006 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
DJ-1's effect on Nrf2 and subsequent effects on antioxidant responses may explain how DJ-1 affects the etiology of both cancer and PD, which are seemingly disparate disorders.
|
17015834 |
2006 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Activation of the Nrf2-ARE signaling pathway: a promising strategy in cancer prevention.
|
16435293 |
2006 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
(2006) provide evidence in a recent issue of Molecular Cell to support the notion that elevated Nrf2 activity may also play a role in the evolution of cancer.
|
16543142 |
2006 |
|
Chemical Carcinogenesis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
Low levels of Nrf2 activity predispose cells to chemical carcinogenesis.Surprisingly, Padmanabhan et al.
|
16543142 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Previous studies suggest that Nrf2 may be constitutively activated in NSCLC.
|
17606720 |
2007 |
|
Carcinogenesis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
These data suggest that cross-talk between Nrf2 and RARalpha could markedly influence the sensitivity of cells to electrophiles and oxidative stressors and, as a consequence, to carcinogenesis.
|
18048326 |
2007 |
|
Carcinogenesis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The genes regulated by Nrf2 are very important for cellular protection of the genome from xenobiotic and oxidative stresses and, consequently, for preventing carcinogenesis.
|
17129360 |
2007 |
|
Gastrointestinal Diseases
|
0.310 |
Biomarker
|
group |
BEFREE |
Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease.
|
17562481 |
2007 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, we showed that atheroprotective flow activates Nrf2 via the phosphoinositol 3-kinase/Akt pathway, and this activation occurs differentially in atherosclerosis-resistant and atherosclerosis-susceptible regions of the mouse aorta.
|
17673673 |
2007 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, we showed that atheroprotective flow activates Nrf2 via the phosphoinositol 3-kinase/Akt pathway, and this activation occurs differentially in atherosclerosis-resistant and atherosclerosis-susceptible regions of the mouse aorta.
|
17673673 |
2007 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity.
|
17822677 |
2007 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using unconditional logistic regression, genetic variations in Nrf2 (11108C>T), NQO1 (609C>T), NOS3 (894G>T), and HO-1 [(GT)(n) dinucleotide length polymorphism] were not associated with breast cancer risk in a multivariate model.
|
17726138 |
2007 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the involvement of Nrf2-mediated oxidative stress responses in breast cancer cells is largely unknown.
|
17875699 |
2007 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Considering the possible role of Prx1 and Nrf2 in radioresistance/chemoresistance, it warrants future investigation to evaluate whether elevated Prx1 and/or Nrf2 levels are predictive of treatment response in advanced lung cancer and other malignancies.
|
17606720 |
2007 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using a human mammary MCF7-derived AREc32 reporter cell line, we now report that all-trans retinoic acid (ATRA), and other retinoic acid receptor alpha (RARalpha) agonists, markedly reduces the ability of Nrf2 to mediate induction of ARE-driven genes by cancer chemopreventive agents including the metabolite of butylated hydroxyanisole, tert-butylhydroquinone (tBHQ).
|
18048326 |
2007 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This implies that enhancing Nrf2 activity is a promising method for thwarting cancer.
|
17129360 |
2007 |
|
Lung Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer.
|
17606720 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
With regards to the liver and gastrointestinal tract, Nrf2 knockout mice are more susceptible to acetaminophen-induced hepatocellular injury, benzo[a]pyrene-induced tumor formation and Fas- and TNFalpha -mediated hepatocellular apoptosis.
|
17562481 |
2007 |